![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1...
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.28 | -10 | 12.8 | 12.96 | 11.4 | 12716 | 12.46178358 | DE |
4 | -1.38 | -10.6976744186 | 12.9 | 13.16 | 11.4 | 16430 | 12.51986597 | DE |
12 | -3.38 | -22.6845637584 | 14.9 | 15.42 | 11.4 | 20278 | 12.94387857 | DE |
26 | 1.2 | 11.6279069767 | 10.32 | 15.42 | 10.24 | 26061 | 12.92973672 | DE |
52 | -5 | -30.2663438257 | 16.52 | 19.18 | 7.89 | 36075 | 11.79343754 | DE |
156 | -19.78 | -63.1948881789 | 31.3 | 36.7 | 5.6 | 31695 | 13.51333156 | DE |
260 | 2.27 | 24.5405405405 | 9.25 | 39 | 5.6 | 32957 | 17.06690395 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions